Anti-estrogen therapy, including aromatase inhibition, is an effective standard of care for postmenopausal patients with ER+ BC, but AI-resistant ER-mutant metastatic disease often develops within a decade of treatment. Here, CYP19A1 is linked to metastatic neoplasm.